Abby Hardy, Author at BioTuesdays

Developments

TG Therapeutics gets FDA fast track designation for ublituximab plus umbralisib

TG Therapeutics (NASDAQ:TGTX) received the FDA fast track designation for the ublituximab plus umbralisib for the treatment of chronic lymphocytic leukemia (CLL). Ublituximab is a glycoengineered anti-CD20 monoclonal...

October 21, 2020

Developments

Cidara updates Phase 2 rezafungin data

Cidara Therapeutics (NASDAQ:CDTX) reported new data from its Phase 2 STRIVE trial evaluating once-weekly rezafungin for the treatment of candidemia and invasive candidiasis. The trial demonstrated that rezafungin...

October 21, 2020

Developments

IntelGenx grants Tetra Bio-Pharma additional rights to Adversa mucoadhesive delivery technology

IntelGenx (TSXV:IGX; OTCQB:IGXT) granted cannabinoid-derived drug developer Tetra Bio-Pharma (TSX:TBP) (OTCQB:TBPMF) additional exclusive worldwide rights to IntelGenx’s Adversa mucoadhesive delivery technology. Adversa...

October 20, 2020

Developments

Inventiva odiparcil gets FDA fast track designation for mucopolysaccharidosis

Inventiva’s (PSE:IVA; NASDAQ:IVA) odiparcil received FDA fast track designation for the treatment of mucopolysaccharidosis (MPS) Type VI, a rare progressive genetic disorder. MPS is caused by deficient versions of the...

October 20, 2020

Developments

Aclaris doses first patient in Phase 2a atopic dermatitis trial

Aclaris Therapeutics (NASDAQ:ACRS) dosed the first patient in its Phase 2a trial evaluating ATI-1777 for the treatment of moderate-to-severe atopic dermatitis ATI-1777 is a topical Janus kinase (JAK) 1/3 inhibitor...

October 20, 2020

Developments

Evofem Biosciences enrolls first patient in Phase 3 STD prevention trial

Evofem Biosciences (NASDAQ:EVFM) enrolled the first patient in its Phase 3 trial evaluating EVO100 for the prevention of urogenital chlamydia and gonorrhea in women. The trial, called EVOGUARD, will enroll 1,730 women...

October 20, 2020

Developments

Selecta gets FDA rare pediatric disease designation for methylmalonic acidemia gene therapy

Selecta Biosciences’ (NASDAQ:SELB) MMA-101 received FDA rare pediatric disease designation for the treatment of methylmalonic acidemia (MMA). MMA is caused by a mutation in the methylmalonyl-CoA mutase gene, which...

October 20, 2020

Feature

Novamind building infrastructure for regulated psychedelic industry

Closely-held Novamind is building the infrastructure required to facilitate safe, legal and medically-supervised psychedelic-assisted therapy. “We saw an opportunity to build a sustainable business in a market that’s...

October 20, 2020

Developments

Anavex reports positive results from Phase 2 Parkinson’s disease trial

Anavex Life Sciences (NASDAQ:AVXL) reported positive results from its Phase 2 study evaluating ANAVEX2-73 for the treatment of Parkinson’s disease dementia. The proof-of-concept study enrolled 132 patients who received...

October 15, 2020

Developments

Titan Pharma to focus on ProNeura-based product development

Titan Pharmaceuticals (NASDAQ:TTNP) reported that it will discontinue U.S. Probuphine sales and wind down commercialization activities as it restructures to focus on ProNeura-based product development. “Marketing of...

October 15, 2020

Author - Abby Hardy

TG Therapeutics gets FDA fast track designation for ublituximab plus umbralisib

Cidara updates Phase 2 rezafungin data

IntelGenx grants Tetra Bio-Pharma additional rights to Adversa mucoadhesive delivery technology

Inventiva odiparcil gets FDA fast track designation for mucopolysaccharidosis

Aclaris doses first patient in Phase 2a atopic dermatitis trial

Evofem Biosciences enrolls first patient in Phase 3 STD prevention trial

Selecta gets FDA rare pediatric disease designation for methylmalonic acidemia gene therapy

Novamind building infrastructure for regulated psychedelic industry

Anavex reports positive results from Phase 2 Parkinson’s disease trial

Titan Pharma to focus on ProNeura-based product development

General

More